



3rd Annual Meeting **American Society of**

Pediatric Neuroradiology

ASPNR 2021: One and Done

January 9, 2021

Scheduled for Central Standard Time

7.5 AMA PRA Category 1 CME Credits
6 SAM Credits will be submitted
#ASPNR21





From the ASPNR Meeting Program Chair

If it's January, it's ASPNR! It is my great pleasure to invite you to attend the **3rd Annual Scientific Meeting of the American Society of Pediatric Neuroradiology**, a virtual meeting on current topics of pediatric neuroradiology! For one day of your time, on January 9, 2021, you can learn about trending topics, earn CME/SA-CMES, and connect with colleagues.

Following our second super successful meeting in Miami in 2020, in response to the COVID-19 pandemic, we will meet online, and we are very excited about the educational potential of this virtual meeting! We have a compressed **one-day program** that brings you the top speakers in our field. Expect to hear in-depth **LIVE LECTURES** on core and critical topics, punctuated by our ever popular **Rapid-Fire Sessions**. **Panel sessions**, including a comprehensive review of **pediatric CNS manifestations of COVID-19** by international experts in the field, will be featured.

From a practical perspective, as the ABR has reduced SA-CMES requirements, you can **meet your annual SA-CMES educational requirements** in the first month of the year – **“One and Done”** - Happy New Year! We plan to offer 7.5 AMA PRA Category 1 Credits and 6 SA-CMES credits for this one day meeting. To tie a bow on it, the meeting will be concluded with our **ever-popular Pediatric Neuroradiology Gameshow** with **big prize money**- winner takes all and your name lives in infamy!

This year's program includes:

- 1 day of solid pediatric neuroradiology education
- Updates in trending topics in Pediatric Neuroradiology
- **Expert Lectures by top leaders in the field delivered LIVE**
- An opportunity to connect with our community online in the time of COVID-19
- Interaction and connection with our greater pediatric neuroradiology community

Please join us virtually for the **ASPNR's 3rd Annual Scientific Meeting on January 9, 2021** for an excellent educational experience, where you will learn about pediatric neuroradiology, exchange ideas, catch up with friends in our chat room, and engage and exercise your competitive juices. **This meeting will thaw you out of deep winter and get you primed for an excellent New Year!!**

Thank you, stay safe, and we will see you online in January!

V. Michelle Silvera MD

3rd Annual ASPNR Scientific Meeting Program Chair
ASPNR Vice President
Mayo Clinic
Rochester, MN

Accreditation

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Northwest Imaging Forums. Northwest Imaging Forums is accredited by the ACCME to provide continuing medical education for physicians.

Northwest Imaging Forums designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Self-Assessment Modules (SAMs): Credits designated “SA-CME” by the American Board of Radiology (ABR) qualify toward fulfilling requirements for Maintenance of Certification (MOC) Part II: Lifelong Learning and Self-assessment.

Target Audience

- General neuroradiologists and pediatric radiologists who want to expand their fund of knowledge in pediatric neuroimaging and stay abreast of new developments.
- Pediatric neuroradiologists who want to learn more about current issues and advances in the field.
- General radiologists seeking to improve their understanding and skills in pediatric neuroimaging.
- Non-radiologists who are interested in understanding neuroimaging perspectives of pediatric neurologic disease in the head, neck, and spine.
- Allied health professionals, medical physicists, and medical researchers interested in learning more about practical aspects of pediatric neuroimaging and emerging research.
- Physicians-in-training, residents, and fellows interested in pediatric neuroradiology.



2020-2021 Program Committee

V. Michelle Silvera, MD

3rd Annual ASPNR Scientific Meeting Program Chair

Aashim Bhatia, MD, MS

Timothy N. Booth MD

Paul A. Caruso MD

Laurence J. Eckel MD

Julie B. Guerin MD

Laura L. Hayes MD

Mark D. Mamlouk MD

David M. Mirsky MD

William T. O'Brien Sr. DO

Susan Palasis MD

Executive Committee 2020-2021

Laurence J. Eckel MD, President

V. Michelle Silvera MD, Vice President

Timothy N. Booth MD, Secretary

Paul A. Caruso MD, Treasurer

Aashim Bhatia MD, MS, Member-At-Large

Manohar M. Shroff MD, FRCPC Member-At-Large

Kristen W. Yeom MD, Member-At-Large

Arastoo Vossough MD, PhD, 1st Past-President

Ashok Panigrahy MD, 2nd Past-President

Susan Palasis MD, 3rd Past-President

Educational Objectives

At the completion of the meeting, attendees should be able to:

- Identify commonly encountered brain, neck, and spine disorders in children.
- Explain general concepts related to pediatric epilepsy, developmental anomalies of the face, and spinal dysraphisms.
- Describe diagnostic imaging nuances of hypothalamic abnormalities and differential considerations.
- Know the proposed changes to the WHO brain tumor classification as it relates to children.
- Describe emerging considerations to diagnosis, assessment, and treatment of CNS complications related to COVID-19 infections in children.
- Discuss characteristics of arteriovenous shunts in the brain in children.
- Know the parameters of the newly proposed pediatric stroke trial for children and understand how it may further understanding of the treatment window.
- Know the current imaging approach to children with Moya Moya disease and the prognostic significance of imaging abnormalities related to this disease.

(7.5 AMA PRA Category 1 CME Credits™/6 SAM Credits will be submitted)

Schedule times and contents are subject to change

Session 1 - SAM Session I

All Bases Covered Part 1

Moderators: Laurence J. Eckel MD, Paul A. Caruso MD,
Laura L. Hayes MD, Kristen W. Yeom MD

- 9:00 Welcome Remarks - Program Chair
- 9:10 Head and Neck: Understanding Facial Clefting and Clinical Correlates - Thomas P. Naidich MD, FACR
- 9:35 Q&A
- 9:40 Spine: Spinal Dysraphisms: Let's Bring Clarity - Andrea Rossi MD
- 10:05 Q&A
- 10:10 Brain: Hypothalamic Lesions - The Spectrum - Louis-Gilbert Vezina MD
- 10:35 Q&A
- 10:40 Rapid Fire Session- Audience Response - Susan Palasis MD, Sumit Pruthi MBBS
- 11:00 **15 Minute Break**

Session 2 - SAM Session II

All Bases Covered Part 2

Moderators: Aashim Bhatia MD, MS, Mark D. Mamlouk MD,
Sarah Milla MD, Judith A. Gadde DO

- 11:15 Brain: Pediatric Epilepsy- The Big Picture - A. James Barkovich MD
- 11:40 Q&A
- 11:45 Vascular: Insight Into Pediatric Arteriovenous Shunts - Mesha Martinez MD
- 12:10 Brain: The New 2021 WHO Classification of CNS Neoplasms: "A Sneak Peak" - Anne G. Osborn MD, FACR
- 12:35 Q&A
- 12:40 Rapid Fire Session- Audience Response - Thierry A.G.M Huismann, MD, PD, EDiNR, EDiPNR, FICIS, Timothy N. Booth MD

60 Minute Lunch Break

- 1:00 Break - Time to Grab a Bite
- 1:10 Dr. Terrie Inder. Aspect/Embrace Sponsored Lecture. MR Imaging in the NICU
- 1:25 Q&A
- 1:30 Dr. Gianpaolo Pirovano. Bracco Sponsored Lecture. Optimizing Safety in Pediatric MRI: New Data, New Approvals
- 1:45 Q&A
- 1:50 Break
- 1:55 ASPNR Society News: "Comings and Goings" - Susan Palasis MD

Session 3 - SAM Session III

ICYMI: Trending Topics in Pediatric Neuroradiology

Moderators: Tina Young Poussaint MD, FACR, Erin Simon Schwartz MD, FACR, Aylin Tekes MD, William T. O'Brien Sr. DO

- 2:00 Announcement
- 2:05 PETITE Pediatric Stroke Trial, What Will We Learn? - Sarah Lee MD
- 2:20 RAPNO: Advantages Over RANO - Zoltan Patay MD, PhD
- 2:35 Q&A

PEDIATRIC COVID-19 UPDATE

Moderator: Kshitij Mankad MBBS

- 2:40 Clinical Presentation of COVID-19 in Children - Dipak Ram MD
- 2:55 COVID-19: Pediatric Infectious Disease Aspects - Larry K. Kocielek MD
- 3:05 CNS Imaging Manifestations of COVID-19 in Children and PECOBIG - Camilla Lindan MD
- 3:25 Pediatric COVID-19 International Panel Discussion - Natalie Boeddaert MD, Dipak Ram MBBS, Larry K. Kocielek MD, Manoelle Kossorotoff MD, Camilla Lindan MD, Susan Palasis MD, V. Michelle Silvera MD, Stavros Stivaros MD

3:45 15 Minute Break

Session 4 - SAM Session IV

Deep Dive Into Moya Moya Disease In Children

Moderators: Arastoo Vossough MD, PhD, Julie B. Guerin MD, Manohar M. Shroff MD, FRCPC, Nicholas V. Stence MD

- 4:00 Introduction and Clinical Diagnosis and Management of Moya Moya Disease - Michael Rivkin MD
- 4:10 Imaging of Moya Moya Disease - Amy Danehy MD
- 4:25 Angiographic Findings in Moya Moya Disease - Darren B. Orbach MD
- 4:35 Surgical Approach to Moya Moya Disease - Edward R. Smith MD
- 4:50 Challenging Patients with Moya Moya Disease, Panel Cases - Amy Danehy MD, Darren B. Orbach MD, Michael Rivkin MD, Edward R. Smith MD
- 5:10 Break

ASPNR GAMESHOW TRIVIA - \$1000 PRIZE MONEY -- "WINNER TAKES ALL"

- 5:15 ASPNR Gameshow Trivia - David M. Mirsky MD
- 5:45 Announcement 4th Annual ASPNR Meeting 2022
- 5:55 Announcement Winners of Gameshow and Rapid Fire Sessions and Closing Comments

Invited Faculty and Moderators

A. James Barkovich, MD

University of California San Francisco, San Francisco, CA

Aashim Bhatia, MD, MS

UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

Nathalie Boeddaert MD

Necker Hospital for Sick Children, Paris, France

Timothy N. Booth MD

UT Southwestern Medical Center Children's Health, Dallas, TX

Paul A. Caruso MD

Massachusetts General Hospital, Boston, MA

Amy Danehy MD

Boston Children's Hospital, Boston, MA

Laurence J. Eckel MD

Mayo Clinic, Rochester, MN

Judith A. Gadde DO

Lurie Children's Hospital, Chicago, IL

Julie B. Guerin MD

Mayo Clinic, Rochester, MN

Laura Hayes MD

Nemours Children's Healthcare System, Orlando, FL

**Thierry A.G.M Huismann MD
PD, EDiNR, EDiPNR, FICIS,**

Texas Children's Hospital, Houston, TX

Larry K. Kociolek

Lurie Children's Hospital, Chicago, IL

Manoelle Kossorotoff MD

Necker Hospital for Sick Children, Paris, France

Sarah Lee MD

Lucille Packard Children's Hospital, Palo Alto, CA

Camilla Lindan MD

University of California San Francisco, San Francisco, CA

Mark D. Mamlouk MD

Kaiser Permanente, Santa Clara, CA

Kshitij Mankad MBBS

Great Ormond Street Hospital, London, UK

Mesha Martinez MD

Riley Children's Hospital, Indianapolis, IN

Sarah Milla MD

Children's Healthcare of Atlanta, Atlanta, GA

David M. Mirsky MD

Children's Hospital Colorado, Aurora, CO

Thomas P. Naidich MD

Mount Sinai Hospital, New York, NY

William T. O'Brien Sr. DO

Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Darren B. Orbach MD

Boston Children's Hospital, Boston, MA

Anne G. Osborn MD, FACR

University of Utah, Salt Lake City, UT

Susan Palasis MD

Lurie Children's Hospital, Chicago, IL

Zoltan Patay MD, PhD

St. Jude Children's Research Hospital, Memphis, TN

Tina Young Poussaint MD, FACR

Boston Children's Hospital, Boston, MA

Sumit Pruthi MBBS

Monroe Carell Jr. Children's Hospital, Nashville, TN

Dipak Ram MBBS

Royal Manchester Children's Hospital, Manchester, UK

Michael Rivkin MD

Boston Children's Hospital, Boston, MA

Andrea Rossi MD

Gaslini Hospital, Genoa, Italy

Erin Simon Schwartz, MD, FACR

Children's Hospital of Philadelphia, Philadelphia, PA

Manohar M. Shroff MD, FRCPC

The Hospital for Sick Children, Toronto, Canada

V. Michelle Silvera MD

Mayo Clinic, Rochester, MN

Edward R. Smith MD

Boston Children's Hospital, Boston, MA

Nicholas V. Stence MD

Children's Hospital Colorado, Aurora, CO

Stavros Stivaros MD

Royal Manchester Children's Hospital, Manchester, UK

Aylin Tekes MD

Johns Hopkins Hospital, Baltimore, MD

Louis-Gilbert Vezina MD

Children's National Hospital, Washington, D.C.

Arastoo Vossough MD, PhD

Children's Hospital of Philadelphia, Philadelphia, PA

Kristen W. Yeom MD

Lucille Packard Children's Hospital, Palo Alto, CA

Registration Information

3rd Annual Scientific Meeting American Society of Pediatric Neuroradiology

Special Pricing due to COVID-19

ASP ^{NR} Member	\$125.00
Non-ASP ^{NR} Member	\$125.00
Members In Training Resident Fellow Medical Student	\$75.00
<small>(Letter from your Chairman or Fellowship Director is required).</small>	
Registrants from low GDP countries (as identified by the RSNA 2020).....	\$75.00

Total Enclosed: \$

4 Easy Ways to Register



<https://aspr.nwforums.com>

Fax/Phone

Phone: (541) 683-4930
Fax: (541) 683-8499
E-mail: members@asprn.org

Mail

Make checks payable / send registration form to:
Northwest Imaging Forums, Inc.
P.O. Box 25909
Eugene, Oregon 97402



Name Degree M.D. D.O. DDS DMD Ph.D Other

Company / Institution

Address City / State / Zip Code / Country


Phone Email (Required for Electronic Syllabus)

Card Number / Card Type: Master Card Visa American Express Discover Expiration Date Security Code






Billing Address City / State / Zip Code / Country

Card Holder Signature

Cancellation: Requests for a refund of registration fees, less a \$50 administrative fee, will be made to those providing notification of cancellation.



Our Platinum Partners



embrace[®]
aspectimaging

Powerful Diagnostic Imaging that Delivers Big for Your Smallest Patients

The Embrace[®] Neonatal MRI System provides quality diagnostic imaging *inside* the NICU, enabling you to make confident clinical decisions, right when they are needed, without disrupting your Radiology schedule or staff.

See for yourself how the Embrace[®] can deliver big for you. Contact our sales team at **615-522-5375** to schedule a demonstration.




A transformative solution for neonatal neuroimaging *inside* the NICU.

Discover more at embracemri.com



LIFE FROM INSIDE

**Bracco Diagnostics Inc. supports
ASPNR 2021**



Our Gold Partners

DOTAREM[®] (gadoterate meglumine) Injection

REAL-WORLD TESTED.
REAL-WORLD
PROVEN.

The Dotarem[®] safety profile has been tested and proven in both clinical studies and more than 30 years of global clinical use.*

Dotarem remains an industry standard for contrast imaging with a low incidence of immediate adverse events for patients of all ages.²⁻⁶

For more information on Dotarem, please see Full Prescribing Information including Boxed Warning and Medication Guide.

OVER **100 MILLION** GLOBAL DOSES ADMINISTERED²

0.007%

Spontaneously Reported Worldwide Adverse Events. (>50 million doses)³

1 Dotarem[®]
The first macrocyclic and ionic GBCA molecule.¹

IMPORTANT SAFETY INFORMATION¹

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

- The risk for NSF appears highest among patients with:
 - Chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or
 - Acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
- For patients at highest risk for NSF, do not exceed the recommended DOTAREM dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.



Indications and Usage

DOTAREM[®] (gadoterate meglumine) injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Contraindications

History of clinically important hypersensitivity reactions to DOTAREM.

Warnings and Precautions

- Hypersensitivity Reactions: Anaphylactic and anaphylactoid reactions have been reported with DOTAREM, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of DOTAREM administration and resolved with prompt emergency treatment.
- Before DOTAREM administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to DOTAREM.
- Administer DOTAREM only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.
- Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by brain, skin, kidney, liver and spleen. The duration of retention also varies by tissue, and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs.
- Consequences of gadolinium retention in the brain have not been established. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention.
- Acute Kidney Injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging.
- Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of DOTAREM. Extravasation into tissues during DOTAREM administration may result in tissue irritation.

Adverse Reactions

- The most common adverse reactions associated with DOTAREM in clinical trials were nausea, headache, injection site pain, injection site coldness and rash.
- Serious adverse reactions in the Postmarketing experience have been reported with DOTAREM. These serious adverse reactions include but are not limited to: arrhythmia, cardiac arrest, respiratory arrest, pharyngeal edema, laryngospasm, bronchospasm, coma and convulsion.

Use in Specific Populations

- Pregnancy: GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. Use only if imaging is essential during pregnancy and cannot be delayed.
- Lactation: There are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk.
- Pediatric Use: The safety and efficacy of DOTAREM at a single dose of 0.1 mmol/kg has been established in pediatric patients from birth (term neonates \geq 37 weeks gestational age) to 17 years of age based on clinical data. The safety of DOTAREM has not been established in preterm neonates. No cases of NSF associated with DOTAREM or any other GBCA have been identified in pediatric patients age 6 years and younger.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the full Prescribing Information, including the patient Medication Guide, for additional important safety information.

*Dotarem was launched globally in 1989 and approved by the FDA for use in the US in 2013.

References: 1. Dotarem [package insert]. Princeton, NJ: Guerbet LLC; Oct 2019. 2. Internal data as of Oct 2019. 3. de Kerviler E et al. Adverse reactions to gadoterate meglumine: review of over 25 years of clinical use and more than 50 million doses. *Invest Radiol.* 2016 Sep;51(9):544-51. 4. Briand Y. Daily Paediatric Use of MRI Contrast Agents: Results of a Multi-Centre Survey. *Proceedings of the 29th Congress of the European Society of Pediatric Radiology.* 1992. 5. Soyer et al. Observational Study on the Safety Profile of Gadoterate Meglumine in 35,499 Patients: The SECURE Study. *J. Magn. Reson. Imag.* 2017; 45: 988-997. 6. Behzadi AH, Zhao Y, Farooq Z, Prince MR. Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. *Radiology.* 2016;286(2):471-482.

Guerbet |

GU12201232

Our Silver Partners




NordicNeuroLab

www.nordicneurolab.com

Do you have a zero sedation mission?

Hospitals with a zero sedation mission do everything they can to improve the patients' experience during an MRI scan. We can support you by providing patient entertainment during the scan so that the patient's attention can be drawn towards something entertaining rather than something unpleasant.



Pediatric Neuroradiology is perhaps the perfect example of the need for precision in medicine. As a longstanding supporter of ASPNR and its commitment to excellence in the field, Philips is pleased to share with you our vision for precision diagnosis in this virtual forum.

Precision Diagnosis embraces the promise of a more direct path through diagnosis and treatment – one that combines the power of imaging, pathology, genomics and longitudinal data with insights from artificial intelligence to drive the right care in the right sequence at the right time.

Together with the pediatric neuroradiology community, we are taking a systems view of imaging, focusing on end-to-end solutions that help you provide consistently high-quality imaging services to drive toward precision diagnosis and help you deliver on the goals of the Quadruple Aim.

Visit us at the following links:

Radiology - <https://www.usa.philips.com/healthcare/medical-specialties/radiology>

MR Neuro - <https://www.usa.philips.com/healthcare/resources/landing/neuro-mr>

MR Webinars - <https://www.usa.philips.com/healthcare/education-resources/technologies/mri/mr-imaging-webinars>


Ultrasound - <https://www.usa.philips.com/healthcare/resources/landing/ultrasound/pediatrics>

Visit our RSNA booth to see our full portfolio of solutions - <https://www.usa.philips.com/healthcare/about/events-calendar/rsna>

Our Silver Partners

Simulate the MRI Environment

with **PSYCHOLOGY SOFTWARE TOOLS** 




- Minimize failed scans**
- Identify claustrophobia**
- Track head movement**
- Movement feedback**
- Train MR staff**



Our Bronze Partners

TOMORROW TODAY



Level up your image quality with **AIR™ Recon DL**


AIR™ Recon DL†, an innovative new reconstruction technology from GE Healthcare based on deep learning, offers a fundamental shift in the balance between image quality and scan time, resulting in TrueFidelity™ MR images that elevate the science of image reconstruction for clinical excellence without conventional compromises.

To learn more, visit gehealthcare.com/air.

† Not yet CE marked on 1.5T. Not available for sale in all regions.
© 2021 General Electric Company – All rights reserved. GE, the GE Monogram and AIR are trademarks of General Electric Company.
JB79133XX



Nova Medical



Nova Medical is a world renowned manufacturer of a wide variety of state-of-the-art medium and high field RF products.



Pediatric Brain Mapping



**Pre-treatment Planning
in Epilepsy, Tumor and
other Neuro Disorders**

- Task fMRI – Simple & Passive Paradigms
- Diffusion Tensor Imaging / Tractography
- MR Perfusion – ASL and DSC
- PET/CT combined with MRI
- Export to PACS, surgical navigation, radiation treatment planning
- In-house and cloud-based solutions

Request a demonstration

advisors@prismclinical.com

Ph: 262-754-3840 @PrismClinical

www.prismclinical.com

Proud supporters of ASPNR



3rd Annual Meeting **American Society of**

Pediatric Neuroradiology

ASPNR 2021: One and Done

January 9, 2021

Scheduled for Central Standard Time

Please visit aspnr.nwforums.com for additional information
or contact Northwest Imaging Forums at (541) 683-4930 or
members@aspnr.org